Triptorelin extended release - Xbrane

Drug Profile

Triptorelin extended release - Xbrane

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Primm srl
  • Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Endometriosis; Prostate cancer

Most Recent Events

  • 21 Dec 2016 Xbrane Biopharma signs an agreement with BioAvenir for sales and marketing of Triptorelin extended release (Spherotide) in Israel
  • 21 Nov 2016 Xbrane signs a non-binding term-sheet with Chinese pharmaceutical company for sales and marketing of Spherotide in China
  • 14 Oct 2015 Xbrane Bioscience acquires Primm Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top